
    
      In locally advanced NSCLC local control has been poor, but with SABR remarkable high local
      control rates with low toxicity have been reported. Currently stage III and inoperable II
      NSCLC patients have been treated with IMRT and concurrent chemotherapy at out institute. In
      this study we will explore the combination of SABR and CFRT with concurrent chemotherapy
    
  